Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2002
12/31/2002US6500868 Method for preventing and treating peripheral neuropathy by administering selegiline
12/31/2002US6500857 Subcutaneous muscle treatment using electronic stimulation and topical compositions
12/31/2002US6500856 For therapy of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators
12/31/2002US6500843 Inhibitors of rotamase enzyme activity
12/31/2002US6500814 Hormonal contraceptive
12/31/2002US6500810 Especially a mixture of phosphatidic acid, phosphatidyl inositol, lysophosphatidic acid, lysophosphatidyl choline and lysophosphatidyl inositol.
12/31/2002US6500809 Neural tissue edema is treated by circulating a hyperoncotic artificial cerebrospinal fluid in the cerebrospinal fluid pathway in the vicinity of edematous tissue to cause the edematous tissue to be dehydrated due to an oncotic gradient
12/31/2002US6500804 Administering a dipeptidyl aminopeptidase effector which is selected from the group consisting of n-(n-substituted glycyl)2-cyanopyrrolidones, n-aminoacyl thiazolidines, n-aminoacyl pyrrolidines
12/31/2002US6500800 Composition and method for causing photodynamic damage to target cells
12/31/2002US6500654 Cardiac-related ankyrin-repeat protein kinase
12/31/2002US6500642 Mammalian cdna which encodes a mammalian mapop-3. it also provides for the use of the cdna, fragments, complements, and variants thereof and of the encoded protein, portions thereof and antibodies thereto for diagnosis and treatment of breast
12/31/2002US6500610 Administering compounds that exhibit phosphodiesterase and cyclooxygenase inhibitory activity and apoptosis induction but prefereably not prostaglandin inhibitory activity on cultured tumor cells
12/31/2002US6500463 Mixing plasticizable matrix material, liquid plasticizer, encapsulant, non-plasticizable non-gelatinized starch, and component for controlling rate of release of encapsulant under low shear and low temperature, forming into pieces, drying
12/31/2002US6500460 Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations into mucosal cavities
12/31/2002US6500418 Stimulating neutrophil function to treat inflammatory bowel disease
12/28/2002CA2391205A1 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
12/27/2002WO2002103971A2 Multicarrier receiver
12/27/2002WO2002103361A1 Method for identification of agents for the treatment of diabetes
12/27/2002WO2002103031A2 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002WO2002103014A2 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells
12/27/2002WO2002103008A2 Templated molecules and methods for using such molecules
12/27/2002WO2002103002A2 Gene associated with leishmania parasite virulence
12/27/2002WO2002103000A2 Methods for modulating gap junctions
12/27/2002WO2002102990A2 Fibroblast growth factor and nucleic acid encoding same
12/27/2002WO2002102984A2 Hdac9 polypeptides and polynucleotides and uses thereof
12/27/2002WO2002102981A2 SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
12/27/2002WO2002102978A2 Human growth hormone antagonists
12/27/2002WO2002102853A2 Cd4-specific antibody trx1 and uses therefor
12/27/2002WO2002102846A2 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state
12/27/2002WO2002102792A1 Novel heterocyclic antibacterial compounds
12/27/2002WO2002102783A1 Tyrosine kinase inhibitors
12/27/2002WO2002102768A2 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
12/27/2002WO2002102414A1 Medicinal compositions
12/27/2002WO2002102401A1 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
12/27/2002WO2002102390A1 Enhanced drug delivery in transdermal systems
12/27/2002WO2002102388A2 Active ingredient combination of e.g. galanthamine or deoxypeganine and e.g. acamprosate or memantine for treating an addiction such as alcoholism
12/27/2002WO2002102381A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
12/27/2002WO2002102377A1 Immune response modifiers for the treatment of periodontal disease
12/27/2002WO2002102376A1 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT
12/27/2002WO2002102370A1 Biofilm degrading or sloughing compositions and methods
12/27/2002WO2002102352A1 Composition for the treatment of diseases which affect animals' hooves
12/27/2002WO2002102315A2 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
12/27/2002WO2002102314A2 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002WO2002102313A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002WO2002102310A2 Proteins associated with cell growth, differentiation, and death
12/27/2002WO2002102306A2 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
12/27/2002WO2002102301A2 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
12/27/2002WO2002102297A2 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
12/27/2002WO2002102232A2 A novel signaling pathway for the production of inflammatory pain and neuropathy
12/27/2002WO2002102229A2 Diagnosing tumorigenicity and determining resistance to anticancer therapy
12/27/2002WO2002102169A2 Synthetic fat composition
12/27/2002WO2002095036A3 A novel intein and uses thereof
12/27/2002WO2002076946A3 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
12/27/2002WO2002072077A3 Use of amino acids, amino acid analogues, sugar phosphates and sugar phosphate analogues for treatment of tumors, treatment of sepsis and immunosuppression
12/27/2002WO2002062335A3 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
12/27/2002WO2002060454A3 Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders
12/27/2002WO2002056874A3 Lipid-based nitric oxide donors
12/27/2002WO2002055720A9 Materials and methods relating to protein aggregation in neurodegenerative disease
12/27/2002WO2002055087B1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
12/27/2002WO2002053142A3 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
12/27/2002WO2002051994A3 Polypeptides
12/27/2002WO2002051420A3 Methods and formulations for the treatment of female sexual dysfunction
12/27/2002WO2002049676A3 Compositions containing inclusion complexes
12/27/2002WO2002047612A3 Dietary supplement compositions
12/27/2002WO2002046181A3 Abca-1 elevating compounds against coronary artery disease or atherosclerosis
12/27/2002WO2002018445A8 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
12/27/2002WO2002012467A3 Drug metabolizing enzymes
12/27/2002WO2002009758A3 Inhibitors of cellular efflux pumps of microbes
12/27/2002WO2002009702A3 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
12/27/2002WO2002005851A8 Enhancement of the action of central and peripheral nervous system agents
12/27/2002WO2002004623A3 ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE
12/27/2002WO2002004514A8 Compositions and methods for the therapy and diagnosis of lung cancer
12/27/2002WO2002002078A3 Improved liposomal camptothecins and uses thereof
12/27/2002WO2001096390A3 Compositions and methods for the therapy and diagnosis of colon cancer
12/27/2002WO2001094587A3 Extracellular messengers
12/27/2002WO2001085937A3 Regulator of g protein signalling (rgs8)
12/27/2002WO2001085095B1 Chiral fluoroquinolizinone arginine salt forms
12/27/2002WO2001078706A9 Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
12/27/2002WO2001052904A9 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
12/27/2002WO2001021574A9 Systems and methods for opening obstructed biological conduits
12/27/2002CA2465075A1 Hdac9 polypeptides and polynucleotides and uses thereof
12/27/2002CA2451874A1 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells
12/27/2002CA2451674A1 Biological response modifier composition and uses thereof
12/27/2002CA2451524A1 Templated molecules and methods for using such molecules
12/27/2002CA2450936A1 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450934A1 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450845A1 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state
12/27/2002CA2450809A1 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002CA2450724A1 Quinazoline and pyrido¬2,3-d|pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450700A1 Trx1 antibody and uses therefor
12/27/2002CA2450666A1 Diagnosing tumorigenicity and determining resistance to anticancer therapy
12/27/2002CA2450590A1 Methods and compositions for inhibiting, preventing or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
12/27/2002CA2450159A1 Methods for modulating gap junctions
12/27/2002CA2450074A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
12/27/2002CA2450067A1 Proteins associated with cell growth, differentiation, and death
12/27/2002CA2449977A1 Human growth hormone antagonists
12/27/2002CA2449754A1 Immune response modifiers for the treatment of periodontal disease
12/27/2002CA2446285A1 Fibroblast growth factor and nucleic acid encoding same
12/27/2002CA2446284A1 Method for identification of agents for the treatment of diabetes
12/27/2002CA2444876A1 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
1 ... 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 ... 1151